- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evidence With Ultra–Long Acting Insulins
Louis S. Christos, RPh: We appreciate, now, that we’re getting head-to-head data (within this space) because, traditionally, it’s always been placebo-controlled data. So, just having comparative data is a step forward in diabetes. Having comparative data to show products that have comparable A1C reduction, but a potential better adverse event profile, is a benefit because, hopefully, you address some of those issues associated with the use of insulin. Now, the question is, who is the right patient for these ultra—long acting products versus your standard basal insulins? And I think, obviously, that goes back to the individualization from the provider perspective. But having, again, the data to show that we are potentially reducing hypoglycemic events with these ultra–long acting products is now providing a benefit, potentially, and addressing some of those concerns with insulin.
In the SWITCH 2 trial, when you look at the reduction in hypoglycemic events, the relative reduction is pretty significant in terms of the percentages. What we’ve done at the P&T [Pharmacy and Therapeutics] committee, though, is, when you look at the absolute reduction, these reductions are shown over the course of patient years. And things that are brought up in a P&T consider how significant of an absolute reduction it is (when you’re looking at absolute numbers and the reductions are only a matter of a couple of events over the course of a year), which is something that we’re still taking into consideration. So, again, even though the data are significant, we’re trying to translate (into a potential), what the real world experience would be and what the significance of these actual reductions are. Now, they are reductions and they’ve showed it in their comparative trial, so they are significant. But for us, that (to the provider) is a benefit because now they have an option. Potentially, if patients are on current therapies and they are having hypoglycemic events, they do have an option to switch now to a product that would potentially lower those risks.
In the DEVOTE trial, again, we saw a comparison versus glargine. What was shown was, again, comparable A1C, but we also saw comparable cardiovascular safety. We did, again, see a reduction in hypoglycemic events, which is where we think the ultra—long acting products are sort of trending toward—as the clinical value for those products is actually the hypoglycemic events reduction.
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
